EMA Authorised: Amvuttra (vutrisiran sodium) — Alnylam Netherlands B.V.

View source ↗

Summary

EMA authorised Amvuttra (vutrisiran) for hereditary transthyretin-mediated amyloidosis with polyneuropathy (familial amyloid neuropathy).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• AMVUTTRA (VUTRISIRAN)

Snippet

Status: Authorised. Therapeutic area: Amyloid Neuropathies, Familial. MAH: Alnylam Netherlands B.V.. Decision date: 05/06/2025. Orphan medicine